While common causes of stroke include large artery atherosclerosis, cardioembolism, small vessel disease, and arterial dissection,1,2 cryptogenic strokes constitute 20-30% of all ischemic strokes3-7. Embolic strokes of undetermined source (ESUS) account for 17% of ischemic strokes and represent 80–90% of cryptogenic cases.8 Thrombotic Thrombocytopenic Purpura (TTP), a microangiopathy secondary to an acquired or congenital ADAMTS-13 deficiency, can cause stroke in less than 10% of cases.9

Pathogenic variants in the KCNQ2 gene cause a spectrum of neonatal onset epilepsy, from self-limited familial neonatal epilepsy (SeLNE; mild end) to d...

Publication date: Available online 28 October 2025

Multiple sclerosis (MS) is the most common immune-mediated neurodegenerative disorder of the central nervous system (CNS), characterized by inflammatory demyelination and axonal/neuronal damage (Ward and Goldman, 2022). Epidemiological studies have revealed a steady increase in the crude prevalence of MS over time, affecting 2.8 million people worldwide in 2020. A similar trend has been identified in Iran, with a pooled prevalence of 100 per 100,000, with the highest rate in Tehran, representing the most common cause of non-traumatic disability in young adults (Mirmosayyeb et al., 2022; Walton et al., 2020).

Chugai Pharmaceutical Co., Ltd. announced that it filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) on August 29 for the anti─cancer agent/humanized anti─VEGF monoclonal

Levodopa is the primary treatment for motor symptoms in Parkinson’s disease (PD), yet its real-world effects on activities of daily living (ADLs) across the day remain unclear. This study used continuous real-world monitoring to examine how levodopa dosing influences walking (basic ADL) and driving (instrumental ADL) in individuals with PD.

Levodopa is the primary treatment for motor symptoms in Parkinson’s disease (PD), yet its real-world effects on activities of daily living (ADLs) across the day remain unclear. This study used continuous real-world monitoring to examine how levodopa dosing influences walking (basic ADL) and driving (instrumental ADL) in individuals with PD.

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced the completion of enrollment for REGENERATE MSA─101, its phase 1